“We must acknowledge...that the most important, indeed, the only, thing we have to offer our students is ourselves. Everything else they can read in a book or discover independently.”
Daniel C. Tosteson, MD, dean for faculty of medicine from 1977-1997, Harvard Medical School
From New England Journal of Medicine 1979
Training Pioneers in Therapeutic Sciences
The Therapeutics Graduate Program focuses on pharmacology, toxicology and drug discovery, emphasizing research in both HMS labs and in real-world internships. Our goal is to provide students with the intellectual tool kit and practical skills necessary to be productive researchers in therapeutics discovery throughout the workforce.
The certificate program offers rigorous, multidisciplinary training relevant to identifying and developing novel therapeutics, understanding and investigating mechanisms of drug action, analyzing the reasons for clinical failures, and developing new compounds and applying them in preclinical and clinical studies to improve the treatment of disease.
This program will provide students with all the tools and skills necessary for these aims, including quantitative skills and modern cutting-edge techniques. This involves elucidating and understanding biological pathways and therapeutic mechanisms, understanding adverse effects to limit toxicity, identifying novel therapeutic targets, and characterizing the pharmacologic profiles (pharmacodynamics and pharmacokinetics) of new compounds. Students will understand the social implications and impact of these activities, and we therefore aim to link this training to industrial, clinical, and regulatory activities and to encourage students to consider their studies in a society-wide context.
Program: Biological Sciences in Public Health
Hometown: Manisa, Türkiye
PI(s): Kristopher Sarosiek
I am a PhD student at Harvard University, focusing on translational oncology and women's health. With over five years of international research experience spanning prestigious institutions such as the German Cancer Research Center, Dana-Farber Cancer Institute, and the University of Toronto, my expertise lies in ovarian and breast cancer research. For my dissertation project, I investigate therapy-associated senescence in ovarian cancer. Currently, I manage the flagship chapter of Nucleate in Boston, deeply committed to translational research. My passion for biotech innovation was cultivated during my role as a business development intern at the Merck Innovation Center in Germany. Combining my research and biotech business experience across the USA, Europe, and the Middle East, I aim to drive impactful change at the intersection of academia and industry. I believe the TGP program will serve as an excellent bridge to reach my future goals.
